Biopharmaceutical News and Research

RSS

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that a presentation of results from its Phase 3 clinical trial of Lymphoseek (technetium 99m tilmanocept) Injection in patients with head and neck squamous cell carcinoma received the 1st Investigator Award at the 2nd InternationaI Symposium on Thoracic and Upper Aerodigestive Malignancies.

15 Apr 2013

Sorbent Therapeutics starts patient dosing in Phase 2b clinical trial of CLP-1001

Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that patient dosing has commenced in its Phase 2b clinical trial of CLP-1001.

12 Apr 2013

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.

11 Apr 2013

Data on PV-10 combination therapy presented at AACR Annual Meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented data on PV-10 combination therapy today at the American Association for Cancer Research Annual Meeting in Washington, DC.

11 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Medicago, IDRI to present Phase I clinical results of H5N1 vaccine at World Vaccine Congress

IDRI, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that they will be presenting positive interim Phase I clinical results for their H5N1 Avian Influenza VLP vaccine candidate "H5N1 vaccine" at the World Vaccine Congress.

9 Apr 2013

Clinical data of two Transgene products to be presented at EASL Conference

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products - TG1050 and TG4040 to treat chronic hepatitis B and chronic hepatitis C, respectively - will be presented in oral presentations at this year's European Association for the Study of the Liver Conference (Amsterdam, Netherlands, April 24-28, 2013).

9 Apr 2013

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that the Instituto de Salud Publica of Chile has approved the Company's protocol for its Phase 2 clinical study of TI-001, intranasal oxytocin, for the treatment of chronic migraine.

9 Apr 2013

GE Healthcare releases next-generation sequencing assay for use in clinical trials

GE Healthcare announced today that Clarient Diagnostic Services, Inc., a GE Healthcare company, will begin offering a next-generation sequencing assay focused on solid tumor targets for use in clinical trials.

8 Apr 2013

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

NewLink Genetics Corporation, a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research 2013 annual meeting.

8 Apr 2013

Lipocine announces favorable Phase I study results for LPCN 1111

Lipocine Inc., a biopharmaceutical company focused on developing innovative oral hormone therapies for men's and women's health, today announced favorable Phase I results for LPCN 1111.

8 Apr 2013

GenSight Biologics announces closing of €32 million Series A financing

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing.

8 Apr 2013

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

Berg - a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach - announced today that it will be presenting four abstracts at the AACR Annual Meeting 2013, in Washington, D.C.

8 Apr 2013

Dual challenges of Medical Education groups

The regulatory and financial environment has made it challenging for Medical Education groups to accomplish their principal goal of educating healthcare practitioners on the safe and effective use of new therapies.

6 Apr 2013

Agios, Foundation Medicine announce diagnostic partnership for cancer metabolism programs

Foundation Medicine, Inc., and Agios Pharmaceuticals, Inc., today announced a multi-year diagnostic partnership for Agios' lead programs in cancer metabolism.

4 Apr 2013

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.

3 Apr 2013

Revance Therapeutics raises $33M in Series E financing

Revance Therapeutics, Inc., a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has raised $33 million of its Series E growth financing.

2 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

N30 Pharmaceuticals, Inc., a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, announced today the presentation of key preclinical data for its novel inhibitors of S-nitrosoglutathione reductase.

2 Apr 2013

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

CureVac GmbH, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA, today announced that it has initiated a double-blind, randomized Phase 2b clinical trial of its RNActive cancer vaccine, CV9104, for the treatment of patients with castration-resistant prostate cancer.

28 Mar 2013

Biopharmaceutical News and Research

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

Sorbent Therapeutics starts patient dosing in Phase 2b clinical trial of CLP-1001

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

Data on PV-10 combination therapy presented at AACR Annual Meeting

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Medicago, IDRI to present Phase I clinical results of H5N1 vaccine at World Vaccine Congress

Clinical data of two Transgene products to be presented at EASL Conference

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

GE Healthcare releases next-generation sequencing assay for use in clinical trials

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

Lipocine announces favorable Phase I study results for LPCN 1111

GenSight Biologics announces closing of €32 million Series A financing

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

Dual challenges of Medical Education groups

Agios, Foundation Medicine announce diagnostic partnership for cancer metabolism programs

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

Revance Therapeutics raises $33M in Series E financing

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

Event guide: 3rd EHS for Biopharma Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News